Total Payments
$358,468
2024 Payments
$50,811
Companies
10
Transactions
461
Medicare Patients
894
Medicare Billing
$76,744
Payment Breakdown by Category
Other$268,431 (74.9%)
Consulting$47,360 (13.2%)
Travel$32,288 (9.0%)
Food & Beverage$8,583 (2.4%)
Research$1,398 (0.4%)
Education$321.97 (0.1%)
Gifts$86.77 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $268,431 | 155 | 74.9% |
| Consulting Fee | $47,360 | 16 | 13.2% |
| Travel and Lodging | $32,288 | 118 | 9.0% |
| Food and Beverage | $8,583 | 153 | 2.4% |
| Unspecified | $1,398 | 12 | 0.4% |
| Education | $321.97 | 6 | 0.1% |
| Gift | $86.77 | 1 | 0.0% |
Payments by Type
General
$357,070
449 transactions
Research
$1,398
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $192,249 | 170 | $0 (2024) |
| Gilead Sciences, Inc. | $117,016 | 197 | $0 (2024) |
| Janssen Products, LP | $26,832 | 46 | $0 (2021) |
| Merck Sharp & Dohme LLC | $18,402 | 27 | $0 (2022) |
| Theratechnologies Inc. | $2,926 | 8 | $0 (2017) |
| GlaxoSmithKline, LLC. | $894.20 | 7 | $0 (2019) |
| Welch Allyn | $86.77 | 1 | $0 (2020) |
| Allergan, Inc. | $37.94 | 3 | $0 (2020) |
| Janssen Biotech, Inc. | $12.12 | 1 | $0 (2019) |
| AbbVie, Inc. | $11.96 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $50,811 | 46 | ViiV Healthcare Company ($45,755) |
| 2023 | $37,664 | 45 | ViiV Healthcare Company ($27,677) |
| 2022 | $44,378 | 35 | ViiV Healthcare Company ($34,693) |
| 2021 | $29,895 | 25 | ViiV Healthcare Company ($22,588) |
| 2020 | $43,906 | 42 | ViiV Healthcare Company ($40,734) |
| 2019 | $72,534 | 127 | Gilead Sciences, Inc. ($36,430) |
| 2018 | $28,289 | 37 | Gilead Sciences, Inc. ($21,342) |
| 2017 | $50,992 | 104 | Gilead Sciences Inc ($27,292) |
All Payment Transactions
461 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 12/20/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,230.00 | General |
| Category: HIV | ||||||
| 12/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 12/17/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $490.00 | General |
| Category: HIV | ||||||
| 11/12/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: HIV | ||||||
| 10/21/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 09/26/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $25.46 | General |
| Category: HIV | ||||||
| 09/25/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 09/23/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,450.00 | General |
| Category: HIV | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $119.81 | General |
| Category: HIV | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $735.00 | General |
| Category: HIV | ||||||
| 08/12/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 08/05/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 07/22/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 07/17/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: HIV | ||||||
| 06/12/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 05/10/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 05/10/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 04/09/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $124.51 | General |
| Category: HIV | ||||||
| 04/01/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 04/01/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 03/27/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 03/27/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 03/27/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,398 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 139 | 234 | $56,702 | $13,313 |
| 2022 | 9 | 256 | 379 | $85,624 | $23,028 |
| 2021 | 8 | 273 | 406 | $52,585 | $21,481 |
| 2020 | 3 | 226 | 420 | $43,165 | $18,921 |
Total Patients
894
Total Services
1,439
Medicare Billing
$76,744
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 140 | $43,180 | $9,878 | 22.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 51 | $11,475 | $2,466 | 21.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 14 | 16 | $800.00 | $466.72 | 58.3% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 14 | 16 | $679.00 | $347.97 | 51.2% |
| 90471 | Administration of vaccine | Office | 2023 | 11 | 11 | $568.00 | $154.20 | 27.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 166 | $50,195 | $12,086 | 24.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 28 | $11,984 | $3,733 | 31.2% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 22 | 25 | $11,025 | $3,291 | 29.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 11 | 28 | $6,160 | $1,407 | 22.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 27 | 28 | $1,400 | $786.26 | 56.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 23 | 26 | $1,586 | $733.85 | 46.3% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 28 | 29 | $1,160 | $610.49 | 52.6% |
| 90471 | Administration of vaccine | Office | 2022 | 29 | 33 | $1,650 | $272.61 | 16.5% |
| 90472 | Administration of vaccine, each additional vaccine | Office | 2022 | 13 | 16 | $464.00 | $107.76 | 23.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 93 | 209 | $35,007 | $14,679 | 41.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 29 | $7,796 | $3,585 | 46.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 52 | 60 | $4,931 | $1,488 | 30.2% |
| 90686 | Vaccine for influenza for administration into muscle, 0.5 ml dosage, quadrivalent, preservation free | Office | 2021 | 31 | 31 | $1,240 | $636.43 | 51.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 33 | 33 | $1,650 | $536.58 | 32.5% |
| 90471 | Administration of 1 vaccine | Office | 2021 | 16 | 19 | $950.00 | $237.96 | 25.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2021 | 11 | 11 | $605.00 | $178.86 | 29.6% |
| 90472 | Administration of vaccine | Office | 2021 | 14 | 14 | $406.00 | $140.28 | 34.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 129 | 281 | $24,130 | $13,050 | 54.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 82 | 121 | $16,861 | $4,264 | 25.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 15 | 18 | $2,174 | $1,607 | 73.9% |
About Dr. Marc Johnson, MD
Dr. Marc Johnson, MD is a Internal Medicine healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265451918.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Johnson, MD has received a total of $358,468 in payments from pharmaceutical and medical device companies, with $50,811 received in 2024. These payments were reported across 461 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($268,431).
As a Medicare-enrolled provider, Johnson has provided services to 894 Medicare beneficiaries, totaling 1,439 services with total Medicare billing of $76,744. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Charlotte, NC
- Active Since 07/19/2006
- Last Updated 07/15/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1265451918
Products in Payments
- DOVATO (Drug) $130,054
- Biktarvy (Drug) $51,206
- CABENUVA (Biological) $33,033
- Genvoya (Drug) $16,662
- DELSTRIGO (Drug) $11,740
- PREZCOBIX (Drug) $11,654
- ZEPATIER (Drug) $6,651
- Symtuza (Drug) $5,613
- Descovy (Drug) $4,082
- Sunlenca (Drug) $3,723
- RUKOBIA (Drug) $2,707
- TIVICAY (Drug) $803.50
- SYMTUZA (Drug) $99.95
- Spot Vital Signs (Device) $86.77
- VIBERZI (Drug) $16.19
- Viekira (Drug) $11.96
- VRAYLAR (Drug) $11.38
- PIFELTRO (Drug) $10.87
- BYSTOLIC (Drug) $10.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Charlotte
Ryan Jacobs, Md, MD
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Saad Usmani, Md, MD
Internal Medicine — Payments: $747,509
Internal Medicine $747,509
Michael Rinaldi, Md, MD
Internal Medicine — Payments: $646,787
Internal Medicine $646,787
Dr. Richard Browne, M.d, M.D
Internal Medicine — Payments: $638,169
Internal Medicine $638,169
Sanjeev Gulati, Md, MD
Internal Medicine — Payments: $598,822
Internal Medicine $598,822
Dr. Raymond Thertulien, M.d, M.D
Internal Medicine — Payments: $584,601
Internal Medicine $584,601